查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2046409

疫苗佐劑市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、類型、應用、地區和競爭格局分類，2021-2031年

Vaccine Adjuvants Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Type, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球疫苗佐劑市場預計將從 2025 年的 8.3 億美元成長到 2031 年的 12.2 億美元，複合年成長率為 6.63%。

疫苗佐劑是添加到疫苗製劑中的特殊藥理製劑，用於增強免疫反應，從而提高疫苗的有效性、持久性和針對抗原的抗體產生。該市場成長的主要驅動力是感染疾病和通用感染疾病的日益流行，這需要提高全球免疫接種覆蓋率和資金籌措。此外，重組疫苗和合成疫苗的結構性轉變（其免疫抗原性低於活病毒疫苗）也催生了對有效佐劑系統的需求，以確保患者獲得足夠的血清學保護，從而進一步推動了該行業的發展。儘管存在這些強勁的成長要素，但由於嚴格的法規結構和安全問題，該行業仍面臨相當大的障礙。某些佐劑可能引起副作用或毒性，導致需要進行全面的臨床審查和漫長的產品核可流程。即使面對高全球需求，這種監管瓶頸也可能嚴重阻礙市場擴張。舉例說明這項行動的規模，聯合國兒童基金會將在 2024 年向 99 個國家提供 27.87 億劑疫苗，凸顯了全球免疫生態系統的重要性。

市場概覽
預測期 2027-2031
市場規模：2025年 8.3億美元
市場規模：2031年 12.2億美元
複合年成長率：2026-2031年 6.63%
成長最快的細分市場 佐劑乳劑
最大的市場 北美洲

市場促進因素

新型佐劑技術的進步正成為市場的主要成長引擎，尤其是在公共衛生策略日益轉向需要強效免疫增強的蛋白質疫苗製劑的情況下。皂素類佐劑（例如 Matrix-M）對於提高下一代疫苗（特別是呼吸道疾病疫苗）的有效性至關重要，因為它們能夠降低疫苗劑量並擴大保護範圍。這項策略轉變得益於近期聯邦政府的資助決策，這些決策優先考慮基於佐劑的平台，而非其他針對特定疫情目標的疫苗研發方法。例如，正如 Novavax 在 2025 年 11 月報告的那樣，賽諾菲獲得了美國生物醫學研究與發展局 (BARDA) 的津貼，用於研發專門使用 Novavax 的 Matrix-M 佐劑的流感大流行候選疫苗。

同時，感染疾病和通用感染疾病的日益蔓延推動了對含佐劑疫苗的持續需求。由於細菌和病毒性地方性疾病在全球範圍內持續存在，醫療衛生系統優先考慮能夠提供持久療效和高抗體反應的疫苗，因此將有效的佐劑系統納入國家免疫規劃至關重要。根據葛蘭素史克（GSK）於2025年2月發布的2024年第四季財報，其含鋁佐劑的B型腦膜炎雙球菌疫苗Vexero的銷售額首次突破10億英鎊，反映出全球需求的持續成長。這種對有效預防的強勁需求正在推動整個行業的擴張，領先企業報告稱其創新產品系列實現了顯著成長。例如，賽諾菲於2025年10月發布的2025年第三季財報詳細顯示，其新上市藥品和疫苗的銷售額成長了40.8%。

市場挑戰

由於嚴格的監管條件和固有的安全隱患，全球疫苗佐劑市場面臨巨大的擴張障礙。佐劑旨在增強免疫反應，因此本身就存在產生有害毒性或誘發自體免疫反應的風險，這使得嚴格的安全性評估至關重要。監管機構要求進行廣泛的臨床試驗和藥物安全監測以降低這些風險，這不可避免地延長了產品研發週期。這迫使製造商在長期安全性研究方面投入大量資金，增加了資本支出，並提高了後期研發失敗的風險。因此，佐劑增強疫苗的上市時間被延長，延遲了潛在收入的獲取，並限制了先進配方的快速應用。

這些日益嚴格的監管措施造成了瓶頸，使得創新產品難以以全球需求的速度上市。為了說明這種研發延誤的嚴重性，國際藥品製造商協會聯合會（IFPMA）在2024年報告稱，仍有超過285種預防性和治療性疫苗候選產品處於開發平臺。如此龐大的數字凸顯了監管障礙和強制性安全檢驗如何使眾多潛在產品停留在研發階段而無法上市，從而有效地減緩了整體成長，儘管免疫生態系統存在著迫切的運營需求。

市場趨勢

佐劑在癌症疫苗中的應用日益廣泛，標誌著癌症治療從傳統的預防性免疫轉向治癒性腫瘤治療，這是一個重要的發展趨勢。與依賴中和抗體的預防性疫苗不同，治療性候選疫苗利用複雜的佐劑系統，例如脂質奈米顆粒和新抗原特異性調變器，來克服免疫耐受，並誘導針對已形成腫瘤的強效細胞毒性T細胞反應。隨著大型製藥企業將個人化免疫療法平台置於傳統治療方法之上，這一趨勢正在迅速加速臨床開發平臺。例如，BioNTech公司2025年3月發布的《企業趨勢報告》顯示，其腫瘤產品線取得了顯著進展，目前有超過20項II期和III期臨床試驗正在進行中，主要集中在佐劑增強的mRNA癌症免疫療法方面。

同時，黏膜和鼻內佐劑的出現正在重塑市場格局，彌補了全身性疫苗在阻斷病毒感染方面固有的限制。這一趨勢的重點在於開發新型佐劑技術，使其能夠穿透黏膜屏障，並在呼吸道中誘導產生強效的分泌型IgA反應，從而在病原體入侵的初始階段提供殺菌免疫。目前，檢驗這些新一代遞送系統（尤其是針對呼吸道病原體）的投資和臨床活動正在增加。根據2025年12月發表於PLOS的最新報道，Castlevax公司已開始招募200名受試者進行一項評估其新型經鼻吸入型疫苗候選藥物療效的II期臨床試驗，這表明粘膜免疫策略正蓬勃發展。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球疫苗佐劑市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品組成（佐劑乳液、病原體成分、皂素類佐劑、顆粒狀佐劑、其他佐劑）
    • 依類型（人類用疫苗佐劑、動物用疫苗佐劑）
    • 按應用領域（調查用途、商業用途）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美疫苗佐劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲疫苗佐劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區疫苗佐劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲疫苗佐劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲疫苗佐劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球疫苗佐劑市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Dynavax Technologies
  • Croda International Plc
  • Gsk Plc
  • Novavax
  • Associated British Foods Plc
  • Agenus Inc.
  • Phibro Animal Health Corporation
  • Merck Kgaa
  • Vaxine Pty Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 18797

The Global Vaccine Adjuvants Market is projected to expand significantly, rising from USD 0.83 Billion in 2025 to USD 1.22 Billion by 2031, at a Compound Annual Growth Rate (CAGR) of 6.63%. Vaccine adjuvants are specialized pharmacological agents integrated into vaccine formulations to enhance the immune response, thereby improving the efficacy, durability, and antibody production against antigens. This market growth is primarily fueled by the increasing prevalence of infectious and zoonotic diseases, which necessitates robust global immunization coverage and funding. Additionally, a structural shift toward recombinant and synthetic vaccines, which inherently possess lower immunogenicity than live-attenuated versions, further drives the industry by creating a demand for effective adjuvant systems to ensure adequate patient seroprotection. Despite these strong growth catalysts, the sector encounters considerable impediments due to stringent regulatory frameworks and safety concerns. Certain adjuvants can induce adverse reactions or toxicity, leading to exhaustive clinical scrutiny and prolonged product approval processes. This regulatory bottleneck can substantially impede market expansion, even in the face of high global demand. Illustrating the sheer operational scale, UNICEF delivered 2.787 billion vaccine doses to 99 countries in 2024, highlighting the critical magnitude of the global immunization ecosystem.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 0.83 Billion
Market Size 2031USD 1.22 Billion
CAGR 2026-20316.63%
Fastest Growing SegmentAdjuvant Emulsions
Largest MarketNorth America

Market Driver

Advancements in novel adjuvant technologies serve as a primary growth engine for the market, especially as public health strategies increasingly pivot toward protein-based vaccine formulations that require robust immune potentiation. Adjuvants like the saponin-based Matrix-M are becoming crucial for enhancing the effectiveness of next-generation vaccines, particularly against respiratory threats, by offering dose-sparing benefits and broader protection. This strategic shift is underscored by recent federal funding decisions that prioritize adjuvanted platforms over other modalities for specific pandemic targets; for instance, Sanofi received a BARDA grant for a pandemic influenza vaccine candidate specifically utilizing Novavax's Matrix-M adjuvant, as reported by Novavax in November 2025.

Concurrently, the rising prevalence of infectious and zoonotic diseases continues to drive demand for established adjuvant-containing immunizations. As endemic bacterial and viral burdens persist globally, healthcare systems are prioritizing vaccines with proven durability and high antibody responses, thereby necessitating the inclusion of effective adjuvant systems in national immunization schedules. According to GSK's Q4 2024 announcement in February 2025, sales of Bexsero, a meningitis B vaccine containing an aluminum-based adjuvant, surpassed £1 billion for the first time, reflecting sustained global uptake. This strong demand for effective prophylaxis underpins the broader sector's expansion, with major players reporting significant gains in their innovative portfolios, exemplified by Sanofi's October 2025 Q3 report detailing a 40.8% growth in sales of its newly launched medicines and vaccines.

Market Challenge

The Global Vaccine Adjuvants Market faces a significant barrier to expansion due to stringent regulatory landscapes and inherent safety concerns. Given that adjuvants are specifically engineered to potentiate immune responses, they carry an intrinsic risk of inducing adverse toxicity or autoimmune reactions, which mandates rigorous safety profiling. Regulatory bodies impose extensive clinical trial phases and pharmacovigilance requirements to mitigate these risks, inevitably extending the product development lifecycle. This forces manufacturers to make substantial investments in long-term safety studies, which elevates capital expenditure and increases the risk of late-stage failure. Consequently, the time-to-market for adjuvant-enhanced vaccines is prolonged, delaying potential revenue streams and limiting the prompt availability of advanced formulations.

This intensified regulatory scrutiny creates a bottleneck where innovative products struggle to achieve commercialization at a pace that aligns with global demand. Illustrating the magnitude of this developmental backlog, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) reported in 2024 that over 285 preventative and therapeutic vaccine candidates remained in the development pipeline. This substantial figure underscores how regulatory hurdles and mandatory safety validations keep a vast number of potential products in research phases instead of entering the market, effectively dampening overall growth momentum despite the urgent operational requirements of the immunization ecosystem.

Market Trends

The expansion of adjuvant applications in therapeutic cancer vaccines represents a critical evolution, moving beyond traditional prophylactic immunization toward curative oncology treatments. Unlike preventative vaccines that rely on neutralizing antibodies, therapeutic candidates leverage sophisticated adjuvant systems, such as lipid nanoparticles and neoantigen-specific modulators, to overcome immune tolerance and stimulate potent cytotoxic T-cell responses against established tumors. This trend is rapidly accelerating clinical development pipelines as major pharmaceutical players prioritize personalized immunotherapy platforms over conventional modalities. BioNTech's March 2025 corporate update, for instance, indicated significant advancement in its oncology pipeline, with over 20 ongoing Phase 2 and Phase 3 clinical trials primarily focused on adjuvant-enhanced mRNA cancer immunotherapies.

Simultaneously, the emergence of mucosal and intranasal adjuvant formulations is reshaping the market by addressing the inherent limitations of systemic vaccines in blocking viral transmission. This trend focuses on developing novel adjuvant technologies capable of permeating mucosal barriers and eliciting robust secretory IgA responses within the respiratory tract, thereby providing sterilizing immunity at the initial port of entry for pathogens. The sector is experiencing increased investment and clinical activity aimed at validating these next-generation delivery systems, particularly for respiratory pathogens. A PLOS update from December 2025 reported that Castlevax initiated recruitment for 200 participants in a Phase 2 clinical trial evaluating the efficacy of its novel intranasal vaccine candidate, signaling growing momentum for mucosal immunization strategies.

Key Market Players

  • Dynavax Technologies
  • Croda International Plc
  • Gsk Plc
  • Novavax
  • Associated British Foods Plc
  • Agenus Inc.
  • Phibro Animal Health Corporation
  • Merck Kgaa
  • Vaxine Pty Ltd

Report Scope

In this report, the Global Vaccine Adjuvants Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Vaccine Adjuvants Market, By Product

  • Adjuvant Emulsions
  • Pathogen Components
  • Saponin-Based Adjuvants
  • Particulate Adjuvants
  • Other Adjuvants

Vaccine Adjuvants Market, By Type

  • Human Vaccine Adjuvants
  • Veterinary Vaccine Adjuvants

Vaccine Adjuvants Market, By Application

  • Research Applications
  • Commercial Applications

Vaccine Adjuvants Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Vaccine Adjuvants Market.

Available Customizations:

Global Vaccine Adjuvants Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Vaccine Adjuvants Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Adjuvant Emulsions, Pathogen Components, Saponin-Based Adjuvants, Particulate Adjuvants, Other Adjuvants)
    • 5.2.2. By Type (Human Vaccine Adjuvants, Veterinary Vaccine Adjuvants)
    • 5.2.3. By Application (Research Applications, Commercial Applications)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Vaccine Adjuvants Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Type
    • 6.2.3. By Application
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Vaccine Adjuvants Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By Application
    • 6.3.2. Canada Vaccine Adjuvants Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By Application
    • 6.3.3. Mexico Vaccine Adjuvants Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By Application

7. Europe Vaccine Adjuvants Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Type
    • 7.2.3. By Application
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Vaccine Adjuvants Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By Application
    • 7.3.2. France Vaccine Adjuvants Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By Application
    • 7.3.3. United Kingdom Vaccine Adjuvants Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By Application
    • 7.3.4. Italy Vaccine Adjuvants Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By Application
    • 7.3.5. Spain Vaccine Adjuvants Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By Application

8. Asia Pacific Vaccine Adjuvants Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Type
    • 8.2.3. By Application
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Vaccine Adjuvants Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By Application
    • 8.3.2. India Vaccine Adjuvants Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By Application
    • 8.3.3. Japan Vaccine Adjuvants Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By Application
    • 8.3.4. South Korea Vaccine Adjuvants Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By Application
    • 8.3.5. Australia Vaccine Adjuvants Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By Application

9. Middle East & Africa Vaccine Adjuvants Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Type
    • 9.2.3. By Application
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Vaccine Adjuvants Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By Application
    • 9.3.2. UAE Vaccine Adjuvants Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By Application
    • 9.3.3. South Africa Vaccine Adjuvants Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By Application

10. South America Vaccine Adjuvants Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Type
    • 10.2.3. By Application
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Vaccine Adjuvants Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By Application
    • 10.3.2. Colombia Vaccine Adjuvants Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By Application
    • 10.3.3. Argentina Vaccine Adjuvants Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Vaccine Adjuvants Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Dynavax Technologies
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Croda International Plc
  • 15.3. Gsk Plc
  • 15.4. Novavax
  • 15.5. Associated British Foods Plc
  • 15.6. Agenus Inc.
  • 15.7. Phibro Animal Health Corporation
  • 15.8. Merck Kgaa
  • 15.9. Vaxine Pty Ltd

16. Strategic Recommendations

17. About Us & Disclaimer